Direct-acting Antiviral Drugs Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 NS3/4A Protease Inhibitors
1.2.3 Nucleoside and Nucleotide NS5B Polymerase Inhibitors
1.2.4 NS5A Inhibitors
1.2.5 Non-Nucleoside NS5B Polymerase Inhibitors
1.3 Market by Application
1.3.1 Global Direct-acting Antiviral Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Ambulatory Surgical Centers
1.3.5 Pharmacies
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Direct-acting Antiviral Drugs Market Perspective (2017-2028)
2.2 Direct-acting Antiviral Drugs Growth Trends by Region
2.2.1 Direct-acting Antiviral Drugs Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Direct-acting Antiviral Drugs Historic Market Size by Region (2017-2022)
2.2.3 Direct-acting Antiviral Drugs Forecasted Market Size by Region (2023-2028)
2.3 Direct-acting Antiviral Drugs Market Dynamics
2.3.1 Direct-acting Antiviral Drugs Industry Trends
2.3.2 Direct-acting Antiviral Drugs Market Drivers
2.3.3 Direct-acting Antiviral Drugs Market Challenges
2.3.4 Direct-acting Antiviral Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Direct-acting Antiviral Drugs Players by Revenue
3.1.1 Global Top Direct-acting Antiviral Drugs Players by Revenue (2017-2022)
3.1.2 Global Direct-acting Antiviral Drugs Revenue Market Share by Players (2017-2022)
3.2 Global Direct-acting Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Direct-acting Antiviral Drugs Revenue
3.4 Global Direct-acting Antiviral Drugs Market Concentration Ratio
3.4.1 Global Direct-acting Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Direct-acting Antiviral Drugs Revenue in 2021
3.5 Direct-acting Antiviral Drugs Key Players Head office and Area Served
3.6 Key Players Direct-acting Antiviral Drugs Product Solution and Service
3.7 Date of Enter into Direct-acting Antiviral Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Direct-acting Antiviral Drugs Breakdown Data by Type
4.1 Global Direct-acting Antiviral Drugs Historic Market Size by Type (2017-2022)
4.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2023-2028)
5 Direct-acting Antiviral Drugs Breakdown Data by Application
5.1 Global Direct-acting Antiviral Drugs Historic Market Size by Application (2017-2022)
5.2 Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Direct-acting Antiviral Drugs Market Size (2017-2028)
6.2 North America Direct-acting Antiviral Drugs Market Size by Type
6.2.1 North America Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
6.2.2 North America Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
6.2.3 North America Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
6.3 North America Direct-acting Antiviral Drugs Market Size by Application
6.3.1 North America Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
6.3.2 North America Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
6.3.3 North America Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
6.4 North America Direct-acting Antiviral Drugs Market Size by Country
6.4.1 North America Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
6.4.2 North America Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Direct-acting Antiviral Drugs Market Size (2017-2028)
7.2 Europe Direct-acting Antiviral Drugs Market Size by Type
7.2.1 Europe Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
7.2.2 Europe Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
7.2.3 Europe Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
7.3 Europe Direct-acting Antiviral Drugs Market Size by Application
7.3.1 Europe Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
7.3.2 Europe Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
7.3.3 Europe Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
7.4 Europe Direct-acting Antiviral Drugs Market Size by Country
7.4.1 Europe Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
7.4.2 Europe Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size (2017-2028)
8.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type
8.2.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
8.3 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application
8.3.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
8.4 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region
8.4.1 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Direct-acting Antiviral Drugs Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Direct-acting Antiviral Drugs Market Size (2017-2028)
9.2 Latin America Direct-acting Antiviral Drugs Market Size by Type
9.2.1 Latin America Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
9.2.2 Latin America Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
9.2.3 Latin America Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
9.3 Latin America Direct-acting Antiviral Drugs Market Size by Application
9.3.1 Latin America Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
9.3.2 Latin America Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
9.3.3 Latin America Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
9.4 Latin America Direct-acting Antiviral Drugs Market Size by Country
9.4.1 Latin America Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
9.4.2 Latin America Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size (2017-2028)
10.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type
10.2.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Direct-acting Antiviral Drugs Market Share by Type (2017-2028)
10.3 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application
10.3.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Direct-acting Antiviral Drugs Market Share by Application (2017-2028)
10.4 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country
10.4.1 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Direct-acting Antiviral Drugs Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Direct-acting Antiviral Drugs Introduction
11.1.4 AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.1.5 AbbVie Inc. Recent Developments
11.2 GSK
11.2.1 GSK Company Details
11.2.2 GSK Business Overview
11.2.3 GSK Direct-acting Antiviral Drugs Introduction
11.2.4 GSK Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.2.5 GSK Recent Developments
11.3 Boehringer Ingelheim
11.3.1 Boehringer Ingelheim Company Details
11.3.2 Boehringer Ingelheim Business Overview
11.3.3 Boehringer Ingelheim Direct-acting Antiviral Drugs Introduction
11.3.4 Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.3.5 Boehringer Ingelheim Recent Developments
11.4 Merck
11.4.1 Merck Company Details
11.4.2 Merck Business Overview
11.4.3 Merck Direct-acting Antiviral Drugs Introduction
11.4.4 Merck Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.4.5 Merck Recent Developments
11.5 Novartis
11.5.1 Novartis Company Details
11.5.2 Novartis Business Overview
11.5.3 Novartis Direct-acting Antiviral Drugs Introduction
11.5.4 Novartis Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.5.5 Novartis Recent Developments
11.6 Beximco Pharmaceuticals
11.6.1 Beximco Pharmaceuticals Company Details
11.6.2 Beximco Pharmaceuticals Business Overview
11.6.3 Beximco Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.6.4 Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.6.5 Beximco Pharmaceuticals Recent Developments
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Direct-acting Antiviral Drugs Introduction
11.7.4 Roche Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.7.5 Roche Recent Developments
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Details
11.8.2 Bristol-Myers Squibb Company Business Overview
11.8.3 Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Introduction
11.8.4 Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.8.5 Bristol-Myers Squibb Company Recent Developments
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Details
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Direct-acting Antiviral Drugs Introduction
11.9.4 Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.9.5 Gilead Sciences Recent Developments
11.10 Janssen (Johnson & Johnson)
11.10.1 Janssen (Johnson & Johnson) Company Details
11.10.2 Janssen (Johnson & Johnson) Business Overview
11.10.3 Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Introduction
11.10.4 Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.10.5 Janssen (Johnson & Johnson) Recent Developments
11.11 Vertex Pharmaceuticals
11.11.1 Vertex Pharmaceuticals Company Details
11.11.2 Vertex Pharmaceuticals Business Overview
11.11.3 Vertex Pharmaceuticals Direct-acting Antiviral Drugs Introduction
11.11.4 Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.11.5 Vertex Pharmaceuticals Recent Developments
11.12 Natco Pharma
11.12.1 Natco Pharma Company Details
11.12.2 Natco Pharma Business Overview
11.12.3 Natco Pharma Direct-acting Antiviral Drugs Introduction
11.12.4 Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2017-2022)
11.12.5 Natco Pharma Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of NS3/4A Protease Inhibitors
Table 3. Key Players of Nucleoside and Nucleotide NS5B Polymerase Inhibitors
Table 4. Key Players of NS5A Inhibitors
Table 5. Key Players of Non-Nucleoside NS5B Polymerase Inhibitors
Table 6. Global Direct-acting Antiviral Drugs Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Direct-acting Antiviral Drugs Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Direct-acting Antiviral Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Direct-acting Antiviral Drugs Market Share by Region (2017-2022)
Table 10. Global Direct-acting Antiviral Drugs Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Direct-acting Antiviral Drugs Market Share by Region (2023-2028)
Table 12. Direct-acting Antiviral Drugs Market Trends
Table 13. Direct-acting Antiviral Drugs Market Drivers
Table 14. Direct-acting Antiviral Drugs Market Challenges
Table 15. Direct-acting Antiviral Drugs Market Restraints
Table 16. Global Direct-acting Antiviral Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Direct-acting Antiviral Drugs Revenue Share by Players (2017-2022)
Table 18. Global Top Direct-acting Antiviral Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2021)
Table 19. Ranking of Global Top Direct-acting Antiviral Drugs Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Direct-acting Antiviral Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Direct-acting Antiviral Drugs Product Solution and Service
Table 23. Date of Enter into Direct-acting Antiviral Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Direct-acting Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 26. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2017-2022)
Table 27. Global Direct-acting Antiviral Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 28. Global Direct-acting Antiviral Drugs Revenue Market Share by Type (2023-2028)
Table 29. Global Direct-acting Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Direct-acting Antiviral Drugs Revenue Share by Application (2017-2022)
Table 31. Global Direct-acting Antiviral Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Direct-acting Antiviral Drugs Revenue Share by Application (2023-2028)
Table 33. North America Direct-acting Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 34. North America Direct-acting Antiviral Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 35. North America Direct-acting Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 36. North America Direct-acting Antiviral Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 37. North America Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Direct-acting Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 40. Europe Direct-acting Antiviral Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 41. Europe Direct-acting Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 42. Europe Direct-acting Antiviral Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 43. Europe Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 44. Europe Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 45. Asia Pacific Direct-acting Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Direct-acting Antiviral Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Direct-acting Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Direct-acting Antiviral Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Direct-acting Antiviral Drugs Market Size by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Direct-acting Antiviral Drugs Market Size by Region (2023-2028) & (US$ Million)
Table 51. Latin America Direct-acting Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 52. Latin America Direct-acting Antiviral Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 53. Latin America Direct-acting Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 54. Latin America Direct-acting Antiviral Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 55. Latin America Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 56. Latin America Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Direct-acting Antiviral Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Direct-acting Antiviral Drugs Market Size by Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Direct-acting Antiviral Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Direct-acting Antiviral Drugs Market Size by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Direct-acting Antiviral Drugs Market Size by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Direct-acting Antiviral Drugs Market Size by Country (2023-2028) & (US$ Million)
Table 63. AbbVie Inc. Company Details
Table 64. AbbVie Inc. Business Overview
Table 65. AbbVie Inc. Direct-acting Antiviral Drugs Product
Table 66. AbbVie Inc. Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 67. AbbVie Inc. Recent Developments
Table 68. GSK Company Details
Table 69. GSK Business Overview
Table 70. GSK Direct-acting Antiviral Drugs Product
Table 71. GSK Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 72. GSK Recent Developments
Table 73. Boehringer Ingelheim Company Details
Table 74. Boehringer Ingelheim Business Overview
Table 75. Boehringer Ingelheim Direct-acting Antiviral Drugs Product
Table 76. Boehringer Ingelheim Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 77. Boehringer Ingelheim Recent Developments
Table 78. Merck Company Details
Table 79. Merck Business Overview
Table 80. Merck Direct-acting Antiviral Drugs Product
Table 81. Merck Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 82. Merck Recent Developments
Table 83. Novartis Company Details
Table 84. Novartis Business Overview
Table 85. Novartis Direct-acting Antiviral Drugs Product
Table 86. Novartis Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 87. Novartis Recent Developments
Table 88. Beximco Pharmaceuticals Company Details
Table 89. Beximco Pharmaceuticals Business Overview
Table 90. Beximco Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 91. Beximco Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 92. Beximco Pharmaceuticals Recent Developments
Table 93. Roche Company Details
Table 94. Roche Business Overview
Table 95. Roche Direct-acting Antiviral Drugs Product
Table 96. Roche Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 97. Roche Recent Developments
Table 98. Bristol-Myers Squibb Company Company Details
Table 99. Bristol-Myers Squibb Company Business Overview
Table 100. Bristol-Myers Squibb Company Direct-acting Antiviral Drugs Product
Table 101. Bristol-Myers Squibb Company Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 102. Bristol-Myers Squibb Company Recent Developments
Table 103. Gilead Sciences Company Details
Table 104. Gilead Sciences Business Overview
Table 105. Gilead Sciences Direct-acting Antiviral Drugs Product
Table 106. Gilead Sciences Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 107. Gilead Sciences Recent Developments
Table 108. Janssen (Johnson & Johnson) Company Details
Table 109. Janssen (Johnson & Johnson) Business Overview
Table 110. Janssen (Johnson & Johnson) Direct-acting Antiviral Drugs Product
Table 111. Janssen (Johnson & Johnson) Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 112. Janssen (Johnson & Johnson) Recent Developments
Table 113. Vertex Pharmaceuticals Company Details
Table 114. Vertex Pharmaceuticals Business Overview
Table 115. Vertex Pharmaceuticals Direct-acting Antiviral Drugs Product
Table 116. Vertex Pharmaceuticals Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 117. Vertex Pharmaceuticals Recent Developments
Table 118. Natco Pharma Company Details
Table 119. Natco Pharma Business Overview
Table 120. Natco Pharma Direct-acting Antiviral Drugs Product
Table 121. Natco Pharma Revenue in Direct-acting Antiviral Drugs Business (2017-2022) & (US$ Million)
Table 122. Natco Pharma Recent Developments
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Direct-acting Antiviral Drugs Market Share by Type: 2021 VS 2028
Figure 2. NS3/4A Protease Inhibitors Features
Figure 3. Nucleoside and Nucleotide NS5B Polymerase Inhibitors Features
Figure 4. NS5A Inhibitors Features
Figure 5. Non-Nucleoside NS5B Polymerase Inhibitors Features
Figure 6. Global Direct-acting Antiviral Drugs Market Share by Application: 2021 VS 2028
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Ambulatory Surgical Centers Case Studies
Figure 10. Pharmacies Case Studies
Figure 11. Others Case Studies
Figure 12. Direct-acting Antiviral Drugs Report Years Considered
Figure 13. Global Direct-acting Antiviral Drugs Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 14. Global Direct-acting Antiviral Drugs Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 15. Global Direct-acting Antiviral Drugs Market Share by Region: 2021 VS 2028
Figure 16. Global Direct-acting Antiviral Drugs Market Share by Players in 2021
Figure 17. Global Top Direct-acting Antiviral Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Direct-acting Antiviral Drugs as of 2021)
Figure 18. The Top 10 and 5 Players Market Share by Direct-acting Antiviral Drugs Revenue in 2021
Figure 19. North America Direct-acting Antiviral Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 20. North America Direct-acting Antiviral Drugs Market Size Market Share by Type (2017-2028)
Figure 21. North America Direct-acting Antiviral Drugs Market Size Market Share by Application (2017-2028)
Figure 22. North America Direct-acting Antiviral Drugs Market Size Share by Country (2017-2028)
Figure 23. United States Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Canada Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Europe Direct-acting Antiviral Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 26. Europe Direct-acting Antiviral Drugs Market Size Market Share by Type (2017-2028)
Figure 27. Europe Direct-acting Antiviral Drugs Market Size Market Share by Application (2017-2028)
Figure 28. Europe Direct-acting Antiviral Drugs Market Size Share by Country (2017-2028)
Figure 29. Germany Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. France Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. U.K. Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Italy Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Russia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Nordic Countries Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Asia-Pacific Direct-acting Antiviral Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 36. Asia Pacific Direct-acting Antiviral Drugs Market Size Market Share by Type (2017-2028)
Figure 37. Asia Pacific Direct-acting Antiviral Drugs Market Size Market Share by Application (2017-2028)
Figure 38. Asia Pacific Direct-acting Antiviral Drugs Market Size Share by Region (2017-2028)
Figure 39. China Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Japan Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. South Korea Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Southeast Asia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. India Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Australia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 45. Latin America Direct-acting Antiviral Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 46. Latin America Direct-acting Antiviral Drugs Market Size Market Share by Type (2017-2028)
Figure 47. Latin America Direct-acting Antiviral Drugs Market Size Market Share by Application (2017-2028)
Figure 48. Latin America Direct-acting Antiviral Drugs Market Size Share by Country (2017-2028)
Figure 49. Mexico Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Brazil Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Middle East & Africa Direct-acting Antiviral Drugs Market Size YoY (2017-2028) & (US$ Million)
Figure 52. Middle East and Africa Direct-acting Antiviral Drugs Market Size Market Share by Type (2017-2028)
Figure 53. Middle East and Africa Direct-acting Antiviral Drugs Market Size Market Share by Application (2017-2028)
Figure 54. Middle East and Africa Direct-acting Antiviral Drugs Market Size Share by Country (2017-2028)
Figure 55. Turkey Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. Saudi Arabia Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. UAE Direct-acting Antiviral Drugs Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 58. AbbVie Inc. Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 59. GSK Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 60. Boehringer Ingelheim Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 61. Merck Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 62. Novartis Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 63. Beximco Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 64. Roche Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 65. Bristol-Myers Squibb Company Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 66. Gilead Sciences Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 67. Janssen (Johnson & Johnson) Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 68. Vertex Pharmaceuticals Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 69. Natco Pharma Revenue Growth Rate in Direct-acting Antiviral Drugs Business (2017-2022)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Industry Market Size
